Baseline tumour measurements predict survival in advanced non-small cell lung cancer

D. E. Gerber, S. E. Dahlberg, A. B. Sandler, D. H. Ahn, J. H. Schiller, J. R. Brahmer, D. H. Johnson

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background:The association between tumour measurements and survival has been studied extensively in early-stage and locally advanced non-small cell lung cancer (NSCLC). We analysed these factors in patients with advanced NSCLC.Methods:Data were derived from the E4599 trial of paclitaxel-carboplatin±bevacizumab. Associations between the Response Evaluation Criteria in Solid Tumors (RECIST) baseline sum longest diameter (BSLD), response rate, progression-free survival (PFS) and overall survival (OS) were evaluated using univariate and multivariable Cox regression models.Results:A total of 759 of the 850 patients (89%) in the E4599 trial had measurable diseases and were included in this analysis. The median BSLD was 7.5 cm. BSLD predicted OS (hazard ratio (HR) 1.41; P<0.001) and had a trend towards association with PFS (HR 1.14; P=0.08). The median OS was 12.6 months for patients with BSLD <7.5 cm compared with 9.5 months for BSLD ≥7.5 cm. This association persisted in a multivariable model controlling multiple prognostic factors, including the presence and sites of extrathoracic disease (HR 1.24; P=0.01). There was no association between BSLD and response rate.Conclusion:Tumour measurements are associated with survival in the E4599 trial. If validated in other populations, this parameter may provide important prognostic information to patients and clinicians.

Original languageEnglish (US)
Pages (from-to)1476-1481
Number of pages6
JournalBritish Journal of Cancer
Volume109
Issue number6
DOIs
StatePublished - Sep 17 2013

Fingerprint

Non-Small Cell Lung Carcinoma
Survival
Neoplasms
Disease-Free Survival
Paclitaxel
Proportional Hazards Models
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Baseline tumour measurements predict survival in advanced non-small cell lung cancer. / Gerber, D. E.; Dahlberg, S. E.; Sandler, A. B.; Ahn, D. H.; Schiller, J. H.; Brahmer, J. R.; Johnson, D. H.

In: British Journal of Cancer, Vol. 109, No. 6, 17.09.2013, p. 1476-1481.

Research output: Contribution to journalArticle

Gerber, D. E. ; Dahlberg, S. E. ; Sandler, A. B. ; Ahn, D. H. ; Schiller, J. H. ; Brahmer, J. R. ; Johnson, D. H. / Baseline tumour measurements predict survival in advanced non-small cell lung cancer. In: British Journal of Cancer. 2013 ; Vol. 109, No. 6. pp. 1476-1481.
@article{354389ea2aa94ccb8603c2728c8addb2,
title = "Baseline tumour measurements predict survival in advanced non-small cell lung cancer",
abstract = "Background:The association between tumour measurements and survival has been studied extensively in early-stage and locally advanced non-small cell lung cancer (NSCLC). We analysed these factors in patients with advanced NSCLC.Methods:Data were derived from the E4599 trial of paclitaxel-carboplatin±bevacizumab. Associations between the Response Evaluation Criteria in Solid Tumors (RECIST) baseline sum longest diameter (BSLD), response rate, progression-free survival (PFS) and overall survival (OS) were evaluated using univariate and multivariable Cox regression models.Results:A total of 759 of the 850 patients (89{\%}) in the E4599 trial had measurable diseases and were included in this analysis. The median BSLD was 7.5 cm. BSLD predicted OS (hazard ratio (HR) 1.41; P<0.001) and had a trend towards association with PFS (HR 1.14; P=0.08). The median OS was 12.6 months for patients with BSLD <7.5 cm compared with 9.5 months for BSLD ≥7.5 cm. This association persisted in a multivariable model controlling multiple prognostic factors, including the presence and sites of extrathoracic disease (HR 1.24; P=0.01). There was no association between BSLD and response rate.Conclusion:Tumour measurements are associated with survival in the E4599 trial. If validated in other populations, this parameter may provide important prognostic information to patients and clinicians.",
author = "Gerber, {D. E.} and Dahlberg, {S. E.} and Sandler, {A. B.} and Ahn, {D. H.} and Schiller, {J. H.} and Brahmer, {J. R.} and Johnson, {D. H.}",
year = "2013",
month = "9",
day = "17",
doi = "10.1038/bjc.2013.472",
language = "English (US)",
volume = "109",
pages = "1476--1481",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Baseline tumour measurements predict survival in advanced non-small cell lung cancer

AU - Gerber, D. E.

AU - Dahlberg, S. E.

AU - Sandler, A. B.

AU - Ahn, D. H.

AU - Schiller, J. H.

AU - Brahmer, J. R.

AU - Johnson, D. H.

PY - 2013/9/17

Y1 - 2013/9/17

N2 - Background:The association between tumour measurements and survival has been studied extensively in early-stage and locally advanced non-small cell lung cancer (NSCLC). We analysed these factors in patients with advanced NSCLC.Methods:Data were derived from the E4599 trial of paclitaxel-carboplatin±bevacizumab. Associations between the Response Evaluation Criteria in Solid Tumors (RECIST) baseline sum longest diameter (BSLD), response rate, progression-free survival (PFS) and overall survival (OS) were evaluated using univariate and multivariable Cox regression models.Results:A total of 759 of the 850 patients (89%) in the E4599 trial had measurable diseases and were included in this analysis. The median BSLD was 7.5 cm. BSLD predicted OS (hazard ratio (HR) 1.41; P<0.001) and had a trend towards association with PFS (HR 1.14; P=0.08). The median OS was 12.6 months for patients with BSLD <7.5 cm compared with 9.5 months for BSLD ≥7.5 cm. This association persisted in a multivariable model controlling multiple prognostic factors, including the presence and sites of extrathoracic disease (HR 1.24; P=0.01). There was no association between BSLD and response rate.Conclusion:Tumour measurements are associated with survival in the E4599 trial. If validated in other populations, this parameter may provide important prognostic information to patients and clinicians.

AB - Background:The association between tumour measurements and survival has been studied extensively in early-stage and locally advanced non-small cell lung cancer (NSCLC). We analysed these factors in patients with advanced NSCLC.Methods:Data were derived from the E4599 trial of paclitaxel-carboplatin±bevacizumab. Associations between the Response Evaluation Criteria in Solid Tumors (RECIST) baseline sum longest diameter (BSLD), response rate, progression-free survival (PFS) and overall survival (OS) were evaluated using univariate and multivariable Cox regression models.Results:A total of 759 of the 850 patients (89%) in the E4599 trial had measurable diseases and were included in this analysis. The median BSLD was 7.5 cm. BSLD predicted OS (hazard ratio (HR) 1.41; P<0.001) and had a trend towards association with PFS (HR 1.14; P=0.08). The median OS was 12.6 months for patients with BSLD <7.5 cm compared with 9.5 months for BSLD ≥7.5 cm. This association persisted in a multivariable model controlling multiple prognostic factors, including the presence and sites of extrathoracic disease (HR 1.24; P=0.01). There was no association between BSLD and response rate.Conclusion:Tumour measurements are associated with survival in the E4599 trial. If validated in other populations, this parameter may provide important prognostic information to patients and clinicians.

UR - http://www.scopus.com/inward/record.url?scp=84884586658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884586658&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.472

DO - 10.1038/bjc.2013.472

M3 - Article

C2 - 23942074

AN - SCOPUS:84884586658

VL - 109

SP - 1476

EP - 1481

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -